A new urinary catheter to prevent biofilm formation and stop #CAUTI

Our IPN silicone enables the development of new medical devices and catheters to prevent the all too frequent hospital acquired infections, like CAUTI. Biomodics' patented IPN technology changes what is possible with silicone in medical devices. It also provides new possibilities in drug delivery.

We're Biomodics

Biomodics specializes in developing silicone with new and improved characteristics. This can be used in developing new medical catheters for health care to reduce hospital acquired infections such as CAUTI and CLABSI. Click here to read more about the company, our mission, and team, and to find out where we are located.

New materials are needed for medical tubing and devices

Silicone is the material of choice for many medical tubing applications like urinary catheters due to its desirable properties such as chemical inertness and high flexibility. However, a common issue with silicone medical tubing is the formation of bacterial biofilm inside and outside the tube often leading to infection. Biomodics' patented IPN technology makes the development of new silicone medical tubing devices resistant to biofilm formation possible. Click here to read more about IPN

Hospital Acquired Infections cause unnecesary suffering

Infections acquired while being treated at a hospital, like Catheter Associated Urinary Tract Infections, CAUTI, and Central Line Associated Blood Stream Infections, CLABSI, stay a serious drawback throughout the world and have immense consequences for the patients with increased morbidity and mortality and unnecessary suffering. The financial consequences of HAIs are also huge. In the United States alone the cost of these infections is estimated at USD 9.8 bil. We at Biomodics believe it time to prevent hospital acquired infection. Click here to read more.
The first Foley catheter featuring IPN silicone

The first Foley catheter to prevent biofilm and stop CAUTI

Biomodics is currently developing a new indwelling urinary catheter to help prevent catheter associated urinary tract infections (CAUTI) by eliminating biofilm formation and subsequent infection. 15-25% of all hospitalized patients will have an indwelling urinary catheter placed, a so-called Foley Catheter. It is no surprise then that CAUTI remains the most common hospital acquired infection. While CAUTI can be often be treated with antibiotics it does lead to an increased length of stay. Sometimes the urinary infection may even cause a potentially fatal bloodstream infection. Biomodics is currently doing pre-clinical testing of a new IPN Foley catheter. In-vitro studies have shown that this effectively inhibits biofilm formation. We strongly believe this will lead to drastic reductions in the number of patients getting a urinary tract infection. After clinical testing, we plan to be able to bring the new catheter to market in 2020.
The supercritical CO2 chamber

Specialists in supercritical CO2 sterlization, extraction, and purification

Biomodics has developed unique competencies and knowledge about supercritical CO2 technology. Supercritical CO2 technology has many advantages and applications. It is currently being used in pharmaceutical and cosmetics industry, in the food sector, as well as in polymer technology. It provides an alternative way of extraction and purification without the use of organic solvents. That means there will be no organic residues. It can also be used working with nanoparticles and polymers. Supercritical CO2 technology also provides a gentler alternative to traditional sterilization methods. Biomodics is participating in a number of research partnerships utilizing scCO2.

Latest news

2016-20-05 Enterprise Europe on Biomodics

Enterprise Europe writes about Biomodics' Eurostar project with Zymetech and Teknologisk Institut. (in Danish) Link to article.

5.12.2016 Biomodics in Medwatch

Biomodics was featured in todays' Medwatch http://medwatch.dk/secure/Medico___Rehab/article8641097.ece

5.8.2016 Biomed

Biomodics will participate in the Biomed conference in Tel Aviv, Israel May 24.26. http://kenes-exhibitions.com/biomed2016/